Cargando…

Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant

INTRODUCTION: Primary graft dysfunction is a major cause of mortality after heart transplantation. OBJECTIVE: To evaluate correlations between donor-related clinical/biochemical markers and the occurrence of primary graft dysfunction/clinical outcomes of recipients within 30 days of transplant. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Braulio, Renato, Sanches, Marcelo Dias, Teixeira Junior, Antonio Lúcio, Costa, Paulo Henrique Nogueira, Moreira, Maria da Consolação Vieira, Rocha, Monaliza Angela, de Andrade, Silvio Amadeu, Gelape, Cláudio Léo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Cirurgia Cardiovascular 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062732/
https://www.ncbi.nlm.nih.gov/pubmed/27556306
http://dx.doi.org/10.5935/1678-9741.20160025
_version_ 1782459842073460736
author Braulio, Renato
Sanches, Marcelo Dias
Teixeira Junior, Antonio Lúcio
Costa, Paulo Henrique Nogueira
Moreira, Maria da Consolação Vieira
Rocha, Monaliza Angela
de Andrade, Silvio Amadeu
Gelape, Cláudio Léo
author_facet Braulio, Renato
Sanches, Marcelo Dias
Teixeira Junior, Antonio Lúcio
Costa, Paulo Henrique Nogueira
Moreira, Maria da Consolação Vieira
Rocha, Monaliza Angela
de Andrade, Silvio Amadeu
Gelape, Cláudio Léo
author_sort Braulio, Renato
collection PubMed
description INTRODUCTION: Primary graft dysfunction is a major cause of mortality after heart transplantation. OBJECTIVE: To evaluate correlations between donor-related clinical/biochemical markers and the occurrence of primary graft dysfunction/clinical outcomes of recipients within 30 days of transplant. METHODS: The prospective study involved 43 donor/recipient pairs. Data collected from donors included demographic and echocardiographic information, noradrenaline administration rates and concentrations of soluble tumor necrosis factor receptors (sTNFR1 and sTNFR2), interleukins (IL-6 and IL-10), monocyte chemoattractant protein-1, C-reactive protein and cardiac troponin I. Data collected from recipients included operating, cardiopulmonary bypass, intensive care unit and hospitalization times, inotrope administration and left/right ventricular function through echocardiography. RESULTS: Recipients who developed moderate/severe left ventricular dysfunction had received organs from significantly older donors (P =0.020). Recipients from donors who required moderate/high doses of noradrenaline (>0.23 µg/kg/min) around harvesting time exhibited lower post-transplant ventricular ejection fractions (P =0.002) and required longer CPB times (P =0.039). Significantly higher concentrations of sTNFR1 (P =0.014) and sTNFR2 (P =0.030) in donors were associated with reduced intensive care unit times (≤5 days) in recipients, while higher donor IL-6 (P =0.029) and IL-10 (P =0.037) levels were correlated with reduced hospitalization times (≤25 days) in recipients. Recipients who required moderate/high levels of noradrenaline for weaning off cardiopulmonary bypass were associated with lower donor concentrations of sTNFR2 (P =0.028) and IL-6 (P =0.001). CONCLUSION: High levels of sTNFR1, sTNFR2, IL-6 and IL-10 in donors were associated with enhanced evolution in recipients. Allografts from older donors, or from those treated with noradrenaline doses >0.23 µg/kg/min, were more frequently affected by primary graft dysfunction within 30 days of surgery.
format Online
Article
Text
id pubmed-5062732
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Sociedade Brasileira de Cirurgia Cardiovascular
record_format MEDLINE/PubMed
spelling pubmed-50627322016-10-19 Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant Braulio, Renato Sanches, Marcelo Dias Teixeira Junior, Antonio Lúcio Costa, Paulo Henrique Nogueira Moreira, Maria da Consolação Vieira Rocha, Monaliza Angela de Andrade, Silvio Amadeu Gelape, Cláudio Léo Braz J Cardiovasc Surg Original Articles INTRODUCTION: Primary graft dysfunction is a major cause of mortality after heart transplantation. OBJECTIVE: To evaluate correlations between donor-related clinical/biochemical markers and the occurrence of primary graft dysfunction/clinical outcomes of recipients within 30 days of transplant. METHODS: The prospective study involved 43 donor/recipient pairs. Data collected from donors included demographic and echocardiographic information, noradrenaline administration rates and concentrations of soluble tumor necrosis factor receptors (sTNFR1 and sTNFR2), interleukins (IL-6 and IL-10), monocyte chemoattractant protein-1, C-reactive protein and cardiac troponin I. Data collected from recipients included operating, cardiopulmonary bypass, intensive care unit and hospitalization times, inotrope administration and left/right ventricular function through echocardiography. RESULTS: Recipients who developed moderate/severe left ventricular dysfunction had received organs from significantly older donors (P =0.020). Recipients from donors who required moderate/high doses of noradrenaline (>0.23 µg/kg/min) around harvesting time exhibited lower post-transplant ventricular ejection fractions (P =0.002) and required longer CPB times (P =0.039). Significantly higher concentrations of sTNFR1 (P =0.014) and sTNFR2 (P =0.030) in donors were associated with reduced intensive care unit times (≤5 days) in recipients, while higher donor IL-6 (P =0.029) and IL-10 (P =0.037) levels were correlated with reduced hospitalization times (≤25 days) in recipients. Recipients who required moderate/high levels of noradrenaline for weaning off cardiopulmonary bypass were associated with lower donor concentrations of sTNFR2 (P =0.028) and IL-6 (P =0.001). CONCLUSION: High levels of sTNFR1, sTNFR2, IL-6 and IL-10 in donors were associated with enhanced evolution in recipients. Allografts from older donors, or from those treated with noradrenaline doses >0.23 µg/kg/min, were more frequently affected by primary graft dysfunction within 30 days of surgery. Sociedade Brasileira de Cirurgia Cardiovascular 2016 /pmc/articles/PMC5062732/ /pubmed/27556306 http://dx.doi.org/10.5935/1678-9741.20160025 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Braulio, Renato
Sanches, Marcelo Dias
Teixeira Junior, Antonio Lúcio
Costa, Paulo Henrique Nogueira
Moreira, Maria da Consolação Vieira
Rocha, Monaliza Angela
de Andrade, Silvio Amadeu
Gelape, Cláudio Léo
Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant
title Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant
title_full Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant
title_fullStr Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant
title_full_unstemmed Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant
title_short Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant
title_sort associated clinical and laboratory markers of donor on allograft function after heart transplant
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062732/
https://www.ncbi.nlm.nih.gov/pubmed/27556306
http://dx.doi.org/10.5935/1678-9741.20160025
work_keys_str_mv AT brauliorenato associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant
AT sanchesmarcelodias associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant
AT teixeirajuniorantoniolucio associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant
AT costapaulohenriquenogueira associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant
AT moreiramariadaconsolacaovieira associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant
AT rochamonalizaangela associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant
AT deandradesilvioamadeu associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant
AT gelapeclaudioleo associatedclinicalandlaboratorymarkersofdonoronallograftfunctionafterhearttransplant